

Yao-Tseng Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12032469/publications.pdf>

Version: 2024-02-01

119
papers

15,401
citations

36203

51
h-index

27345

106
g-index

122
all docs

122
docs citations

122
times ranked

14737
citing authors

#	ARTICLE	IF	CITATIONS
1	Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18538-18543.	3.3	2,100
2	Cancer/testis antigens, gametogenesis and cancer. Nature Reviews Cancer, 2005, 5, 615-625.	12.8	1,415
3	Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunological Reviews, 2002, 188, 22-32.	2.8	739
4	Simultaneous Humoral and Cellular Immune Response against Cancerâ€“Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2â€“binding Peptide Epitopes. Journal of Experimental Medicine, 1998, 187, 265-270.	4.2	668
5	A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens. Journal of Experimental Medicine, 1998, 187, 1349-1354.	4.2	642
6	Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Science, 2009, 100, 2014-2021.	1.7	478
7	New Paths in Human Cancer Serology. Journal of Experimental Medicine, 1998, 187, 1163-1167.	4.2	433
8	Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10697-10702.	3.3	411
9	CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Research, 2009, 37, D816-D819.	6.5	338
10	NYâ€“ESOâ€“1: Review of an Immunogenic Tumor Antigen. Advances in Cancer Research, 2006, 95, 1-30.	1.9	311
11	Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. International Journal of Cancer, 2001, 92, 856-860.	2.3	310
12	Genome-wide analysis of cancer/testis gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20422-20427.	3.3	295
13	Characterization of human colon cancer antigens recognized by autologous antibodies. , 1998, 76, 652-658.		281
14	Colon cancer associated transcriptâ€“1: A novel RNA expressed in malignant and preâ€“malignant human tissues. International Journal of Cancer, 2012, 130, 1598-1606.	2.3	250
15	A103. American Journal of Surgical Pathology, 1998, 22, 595-602.	2.1	233
16	Expression of Melan-A (MART1) in Benign Melanocytic Nevi and Primary Cutaneous Malignant Melanoma. American Journal of Surgical Pathology, 1998, 22, 976-982.	2.1	227
17	Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101â€“0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1â€“Expressing Melanoma. Journal of Experimental Medicine, 2000, 191, 625-630.	4.2	196
18	MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Modern Pathology, 2008, 21, 1139-1146.	2.9	195

#	ARTICLE	IF	CITATIONS
19	Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: Correlation with clinical events. , 1999, 84, 506-510.		194
20	NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Research, 2003, 63, 6076-83.	0.4	191
21	SSX: A multigene family with several members transcribed in normal testis and human cancer. , 1997, 72, 965-971.		190
22	Expression of MAGE-antigens in normal tissues and cancer. International Journal of Cancer, 2000, 85, 460-465.	2.3	179
23	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8862-8867.	3.3	179
24	Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients. Journal of Immunology, 2004, 172, 3289-3296.	0.4	176
25	The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood, 2005, 106, 167-174.	0.6	172
26	Seromic profiling of ovarian and pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5088-5093.	3.3	163
27	Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL. Journal of Immunology, 2000, 165, 948-955.	0.4	161
28	Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Modern Pathology, 2007, 20, 921-928.	2.9	155
29	Clinical, Pathologic, and Molecular Features of Early-onset Colorectal Carcinoma. American Journal of Surgical Pathology, 2009, 33, 572-582.	2.1	152
30	Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Research, 2002, 62, 4041-7.	0.4	149
31	Antigens recognized by autologous antibody in patients with renal-cell carcinoma. , 1999, 83, 456-464.		146
32	Expression of SSX genes in human tumors. , 1998, 77, 19-23.		143
33	Diagnostic Usefulness of HBME1, Galectin-3, CK19, and CITED1 and Evaluation of Their Expression in Encapsulated Lesions With Questionable Features of Papillary Thyroid Carcinoma. American Journal of Clinical Pathology, 2006, 126, 700-708.	0.4	128
34	Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer, 2003, 42, 23-33.	0.9	123
35	Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Letters, 2000, 150, 155-164.	3.2	117
36	Identification of cancer/testis genes by database mining and mRNA expression analysis. International Journal of Cancer, 2002, 98, 485-492.	2.3	111

#	ARTICLE	IF	CITATIONS
37	Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7940-7945.	3.3	109
38	TheSSXgene family: Characterization of 9 complete genes. International Journal of Cancer, 2002, 101, 448-453.	2.3	106
39	CT10: A new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. , 2000, 85, 726-732.		105
40	Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies. , 1998, 78, 387-389.		99
41	Immunomic analysis of human sarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2651-2656.	3.3	98
42	NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors. Cancer Research, 2004, 64, 2199-2204.	0.4	92
43	CT-X antigen expression in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13493-13498.	3.3	92
44	MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. , 1997, 33, 233-239.		85
45	Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers. PLoS ONE, 2011, 6, e17876.	1.1	84
46	CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11813-11818.	3.3	83
47	Gene Expression Profiling Separates Chromophobe Renal Cell Carcinoma from Oncocytoma and Identifies Vesicular Transport and Cell Junction Proteins as Differentially Expressed Genes. Clinical Cancer Research, 2006, 12, 6937-6945.	3.2	79
48	Real-Time, label-free monitoring of tumor antigen and serum antibody interactions. Journal of Proteomics, 2004, 61, 283-298.	2.4	78
49	T311â€”An Anti-Tyrosinase Monoclonal Antibody for the Detection of Melanocytic Lesions in Paraffin Embedded Tissues. Pathology Research and Practice, 2000, 196, 235-242.	1.0	73
50	Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer, 2005, 103, 2575-2583.	2.0	72
51	Bcl-xL promotes metastasis independent of its anti-apoptotic activity. Nature Communications, 2016, 7, 10384.	5.8	68
52	NY-ESO-1 protein expression in primary breast carcinoma and metastasesâ€”correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. International Journal of Cancer, 2007, 120, 2411-2417.	2.3	65
53	NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer. Clinical Cancer Research, 2004, 10, 6551-6558.	3.2	62
54	CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. International Journal of Cancer, 2002, 99, 839-845.	2.3	60

#	ARTICLE	IF	CITATIONS
55	Microarray Analysis of Thyroid Nodule Fine-Needle Aspirates Accurately Classifies Benign and Malignant Lesions. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 490-498.	1.2	57
56	Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein. <i>Cancer Immunity</i> , 2005, 5, 9.	3.2	56
57	Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1. <i>Clinical Cancer Research</i> , 2004, 10, 8396-8404.	3.2	55
58	NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1723-1731.	2.0	55
59	Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer. <i>International Journal of Cancer</i> , 2009, 124, 2893-2898.	2.3	53
60	PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. <i>Cancer Immunity</i> , 2007, 7, 18.	3.2	51
61	Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs. <i>Journal of Immunology</i> , 2003, 170, 1191-1196.	0.4	50
62	Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1999, 434, 429-435.	1.4	48
63	Autoantibodies Against Cancer Antigens. <i>Methods in Molecular Biology</i> , 2009, 520, 11-19.	0.4	45
64	Messenger RNA Expression Ratios among Four Genes Predict Subtypes of Renal Cell Carcinoma and Distinguish Oncocytoma from Carcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 6558-6566.	3.2	42
65	Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases. <i>Clinical Cancer Research</i> , 2006, 12, 2745-2751.	3.2	42
66	Identification of borderline thyroid tumors by gene expression array analysis. <i>Cancer</i> , 2009, 115, 5421-5431.	2.0	40
67	Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. <i>Endocrine-Related Cancer</i> , 2019, 26, 47-57.	1.6	39
68	Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. <i>Cancer Immunity</i> , 2005, 5, 11.	3.2	39
69	Isoforms of the human PDZ-73 protein exhibit differential tissue expression. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1999, 1445, 39-52.	2.4	37
70	Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. <i>Human Reproduction</i> , 2011, 26, 3232-3243.	0.4	37
71	IFN- γ enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14467-14472.	3.3	36
72	Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 3093-3098.	3.3	35

#	ARTICLE	IF	CITATIONS
73	Identification of a new cancer/testis gene family, CT47 , among expressed multicopy genes on the human X chromosome. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 392-400.	1.5	34
74	Tla-region genes and their products. <i>Immunologic Research</i> , 1987, 6, 30-45.	1.3	33
75	NY-BR-1 is a Differentiation Antigen of the Mammary Gland. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 77-83.	0.6	33
76	Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing. <i>Modern Pathology</i> , 2018, 31, 1756-1766.	2.9	33
77	ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3291-3298.	3.2	32
78	Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1281-1285.	1.4	31
79	The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e67876.	1.1	31
80	Cancer-Testis Antigen Expression in Digestive Tract Carcinomas: Frequent Expression in Esophageal Squamous Cell Carcinoma and Its Precursor Lesions. <i>Cancer Immunology Research</i> , 2014, 2, 480-486.	1.6	31
81	Immunohistochemical analysis of RHAMM expression in normal and neoplastic human tissues: a cell cycle protein with distinctive expression in mitotic cells and testicular germ cells. <i>Oncotarget</i> , 2018, 9, 20941-20952.	0.8	29
82	Identification of cancer antigens in breast cancer by the SEREX expression cloning method. <i>Breast Cancer</i> , 1999, 6, 305-311.	1.3	28
83	Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2018, 12, 221-229.	1.3	27
84	A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved. <i>Gene</i> , 2002, 297, 141-149.	1.0	26
85	Effects of CT-Xp Gene Knock down in Melanoma Cell Lines. <i>Oncotarget</i> , 2013, 4, 531-541.	0.8	23
86	Identification and characterization of mouse SSX genes: a multigene family on the X chromosome with restricted cancer/testis expression. <i>Genomics</i> , 2003, 82, 628-636.	1.3	22
87	CD4+ T Cell Responses to SSX-4 in Melanoma Patients. <i>Journal of Immunology</i> , 2005, 174, 5092-5099.	0.4	20
88	Distinct expression patterns of the immunogenic differentiation antigen NY-ESO-1 in normal breast, testis and their malignant counterparts. <i>International Journal of Cancer</i> , 2008, 122, 1585-1591.	2.3	20
89	Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 191, 830-841.	0.2	19
90	SEREX analysis of gastric cancer antigens. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, S37-S42.	1.1	18

#	ARTICLE	IF	CITATIONS
91	Survivin as a Useful Adjunct Marker for the Grading of Papillary Urothelial Carcinoma. Archives of Pathology and Laboratory Medicine, 2008, 132, 224-231.	1.2	18
92	Identification of an SSX-2 Epitope Presented by Dendritic Cells to Circulating Autologous CD4+ T Cells. Journal of Immunology, 2004, 172, 7206-7211.	0.4	17
93	Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clinical Immunology, 2005, 114, 70-78.	1.4	17
94	Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunology, Immunotherapy, 2006, 56, 249-258.	2.0	17
95	Expression of cancer/testis (CT) antigens in squamous cell carcinoma of the head and neck: Evaluation as markers of squamous dysplasia. Pathology Research and Practice, 2013, 209, 721-726.	1.0	17
96	Immunohistochemical and Reverse Transcription-Polymerase Chain Reaction Expression Analysis of Tyrosinase and Microphthalmia-Associated Transcription Factor in Angiomyolipomas. Applied Immunohistochemistry & Molecular Morphology, 2001, 9, 29-34.	2.0	15
97	High levels of truncated RHAMM cooperate with dysfunctional p53 to accelerate the progression of pancreatic cancer. Cancer Letters, 2021, 514, 79-89.	3.2	14
98	Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immunity, 2002, 2, 12.	3.2	14
99	SSX antigens as tumor vaccine targets in human sarcoma. Cancer Immunity, 2003, 3, 13.	3.2	13
100	Expression of the Receptor for Hyaluronic Acid-Mediated Motility (RHAMM) in Endometrial Cancer is Associated With Adverse Histologic Parameters and Tumor Progression. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 453-459.	0.6	12
101	Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data mining. NAR Cancer, 2020, 2, zcaa009.	1.6	11
102	Classifying Lung Neuroendocrine Neoplasms through MicroRNA Sequence Data Mining. Cancers, 2020, 12, 2653.	1.7	11
103	Cancer/Testis Antigens: Potential Targets for Immunotherapy. , 2012, , 347-369.		10
104	Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals. Cancer Immunology, Immunotherapy, 2007, 56, 1183-1192.	2.0	8
105	CT7 (MAGE-C1)-Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients.. Blood, 2005, 106, 356-356.	0.6	6
106	RHAMMB-mediated bifunctional nanotherapy targeting Bcl-xL and mitochondria for pancreatic neuroendocrine tumor treatment. Molecular Therapy - Oncolytics, 2021, 23, 277-287.	2.0	5
107	Detection of cancer/testis antigens as a diagnostic tool in routine pathology practice. Oncolimmunology, 2014, 3, e28132.	2.1	4
108	A cautionary note on the immunohistochemical detection of braf v600e mutations in serrated lesions of the colon. Modern Pathology, 2015, 28, 740-741.	2.9	3

#	ARTICLE	IF	CITATIONS
109	The journey from autologous typing to SEREX, NY-ESO-1, and cancer/testis antigens. <i>Cancer Immunity</i> , 2012, 12, 8.	3.2	3
110	Chromosome X-encoded Cancer/Testis antigens are less frequently expressed in non-seminomatous germ cell tumors than in seminomas. <i>Cancer Immunity</i> , 2013, 13, 10.	3.2	3
111	Cancer testis antigen expression in testicular germ cell tumors and in intratubular germ cell neoplasia. <i>Modern Pathology</i> , 2015, 28, 742-744.	2.9	2
112	Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number. <i>International Journal of Oncology</i> , 2005, 26, 57.	1.4	1
113	Minocycline-induced black bone disease with synovial pigmentation in a patient undergoing revision anterior cruciate ligament surgery: A case report. <i>International Journal of Surgery Case Reports</i> , 2021, 81, 105819.	0.2	1
114	Characterization of human colon cancer antigens recognized by autologous antibodies. , 1998, 76, 652.		1
115	Expression of MAGE-antigens in normal tissues and cancer. , 2000, 85, 460.		1
116	Host Immune Responses Against CT Antigens in Multiple Myeloma Patients.. <i>Blood</i> , 2006, 108, 3492-3492.	0.6	1
117	Immunohistochemical and Reverse Transcription-Polymerase Chain Reaction Expression Analysis of Tyrosinase and Microphthalmia-Associated Transcription Factor in Angiomyolipomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2001, 9, 29-34.	0.6	0
118	High Interobserver Variability and Frequent Overdiagnosis of Dysplasia in Fundic Gland Polyps can be Improved by Detecting Atypia on Surface Epithelium and An Abrupt Transition to Non-Neoplastic Cells. <i>Histopathology</i> , 2021, , .	1.6	0
119	NY-ESO-1 as a predictive and prognostic marker in NSCLC.. <i>Journal of Clinical Oncology</i> , 2012, 30, e17539-e17539.	0.8	0